Xention Extends Pact with Ono | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK biopharmaceutical firm Xention said today it has extended its drug discovery agreement with Japanese firm Ono Pharmaceutical for an additional year.

The companies originally signed their two-year agreement in March 2009 and have been successful in identifying multiple compounds, which selectively modulate the function of target ion channels, Xention said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.